StudyFinder
Search Results
1 Study Matches
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
A phase 3 clinical trial to investigate the effectiveness and safety of a study drug in subjects in Idiopathic Pulmonary Fibrosis
You will be required to attend 8 in-person visits at the Hershey Medical Center over the span of approximately one year. During the study you will have physical examinations, complete questionnaires, review your medical history and current medications, have vital signs and ECGs taken, have blood tests performed, complete pulmonary function testing, and potentially have a high resolution CT scan done. You will take the inhaled treprostinil or placebo daily at home throughout the study.
Maris Pedlow - at mpedlow@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
NCT04708782
STUDY00020859
Inclusion Criteria:
At least 40 years of ageDiagnosed with Idiopathic Pulmonary Fibrosis
Exclusion Criteria:
Taking both Esbriet (pirfenidone) and Ofev (nintedanib)Female participants who are pregnant or lactating
Receiving more than 10 L/min of oxygen supplementation at rest
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”